Coverage
-
November 27, 2017
The U.S. Department of the Treasury and the Internal Revenue Service announced on Monday that they are appealing a Texas federal court's decision to invalidate the anti-inversion rule that sank a planned $160 billion merger between Pfizer Inc. and Irish counterpart Allergan PLC.
9 other articles on this case.
View all »